Nabilakhyar (Talk | contribs) |
|||
Line 37: | Line 37: | ||
<h1 style="text-align: center;"><strong>Improvement on Downstream Processing</strong></h1> | <h1 style="text-align: center;"><strong>Improvement on Downstream Processing</strong></h1> | ||
<div class="column two_third_size"> | <div class="column two_third_size"> | ||
− | <p style="text-align: justify;">Another | + | <p style="text-align: justify;">Another main limiting factor that the PHBV production is currently facing which hinders its commercialisation is the inefficient downstream processing which includes PHBV recovery from the microbial cells. This point is supported by our <a href="https://2018.igem.org/Team:Edinburgh_OG/life_cycle_assessment">Life Cycle Assessment</a> as well as our discussion with <a href="https://2018.igem.org/Team:Edinburgh_OG/Human_Practices">Cambridge Consultant</a>. To address this issue, we propose an in-situ secretion system by the <em>E. coli</em> which potentially will be more environmentally friendly and time-efficient.</p> |
<h2>The phasin and hemolysin secretion system (hemolysin BD and hemolysin A)</h2> | <h2>The phasin and hemolysin secretion system (hemolysin BD and hemolysin A)</h2> | ||
<h3><strong>Overview</strong></h3> | <h3><strong>Overview</strong></h3> |
Revision as of 18:47, 17 October 2018